• OPEN AN ACCOUNT
Indian Indices
Sensex
83,021.75 989.94
( 1.21%)
Global Indices
Nasdaq
50,205.66 -574.76
(-1.13%)
Dow Jones
7,342.05 -19.48
(-0.26%)
Hang Seng
59,472.71 448.43
(0.76%)
Nikkei 225
10,468.58 -82.59
(-0.78%)
Forex
USD-INR
93.54 -0.42
(-0.44%)
EUR-INR
102.90 -0.55
(-0.53%)
GBP-INR
123.45 -0.54
(-0.44%)
JPY-INR
0.59 0.00
(-0.28%)

EQUITY - MARKET SCREENER

Kanel Industries Ltd
Industry :  Trading
BSE Code
ISIN Demat
Book Value()
500236
INE252C01023
8.6013936
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
KANELOIL
0
100.85
EPS(TTM)
Face Value()
Div & Yield %
0
10
0
 

Shilpa Medicare Unit VII inspection ends with one procedural observation
Sep 19,2026
The inspection concluded with one procedural observation, which was neither a repeat observation nor related to data integrity. The company will submit a comprehensive response to the USFDA within the stipulated timeline, along with appropriate corrective and preventive actions.

The company said it does not expect the observation to have any material impact on its current business operations or existing supplies from the facility.

Shilpa Medicare is a diversified pharmaceutical and biotechnology company engaged in the development and manufacture of complex generics, biologics and active pharmaceutical ingredients (APIs). Through its subsidiary Shilpa Biologicals, the company operates a fully integrated biologics platform spanning development, scale-up and commercial manufacturing at its EU-GMP facility in Dharwad, India.

The pharmaceutical company‘s consolidated net profit jumped 115.19% year-on-year to Rs 100.88 crore in Q1 FY27 from Rs 46.88 crore in the corresponding quarter last year. Revenue from operations increased 44.89% YoY to Rs 465.78 crorereflecting broad-based growth across its API, formulations and biologics businesses.

The counter rallied 6.63% to settle at Rs 1020.90 on the BSE.